COMBINATION THERAPY WITH ROSUVASTATIN AND EZETIMIBE (TREZETE) IN VERY HIGH CARDIOVASCULAR RISK DYSLIPIDEMIA: EVIDENCE OF EFFICACY AND CLINICAL IMPACT
DOI:
https://doi.org/10.56238/levv16n54-030Keywords:
Dyslipidemia, Rosuvastatin, Ezetimibe, Combination Therapy, Cardiovascular RiskAbstract
Very high cardiovascular risk dyslipidemia requires effective and safe strategies for intensive LDL-C reduction. This integrative review analyzed studies published between 2015 and 2025 on the combination of rosuvastatin and ezetimibe in high cardiovascular risk contexts. The literature search was conducted in PubMed, Scopus, Web of Science, SciELO, LILACS, and ScienceDirect databases. The combination demonstrated an additional LDL-C reduction of up to 25% compared to monotherapy, with a favorable safety profile and improved adherence, especially in fixed-dose formulations. Consistent results were observed in subgroups such as diabetic patients, the elderly, and those with coronary artery disease. The main limitations included short follow-up periods and a lack of comparative studies with newer lipid-lowering therapies. It is concluded that the rosuvastatin/ezetimibe combination is an effective, safe, and applicable therapeutic alternative for very high-risk populations and should be considered a first-line option in intensive cardiovascular prevention settings.
Downloads
References
AKYE, L. N.; KIRK, G. D.; KWON, S. Y. Rosuvastatin and Ezetimibe for Lipid Control in Dyslipidemia. American Journal of Preventive Cardiology, v. 10, n. 2, p. 81–88, 2025. DOI: https://doi.org/10.1016/j.ajpc.2025.07.015.
BAK, S. H. et al. Efficacy and safety of low-dose rosuvastatin/ezetimibe for dyslipidemia in patients with rheumatoid arthritis or osteoarthritis. Medicine, v. 104, n. 40, p. e33440, 2025. Disponível em: https://journals.lww.com/md-journal/fulltext/2025/07040/efficacy_and_safety_of_low_dose.101.aspx.
BRIE, D. M. et al. Dyslipidemia treatment in patients with acute coronary syndrome: is it time to move to combination therapy? Journal of Clinical Medicine, v. 14, n. 18, p. 6445, 2025. DOI: https://doi.org/10.3390/jcm14186445.
DODULÍK, J. et al. Triple non-statin therapy with ezetimibe, inclisiran, and bempedoic acid in patients with genetically confirmed statin-induced rhabdomyolysis: a dual case report. Pharmaceuticals, v. 18, n. 6, p. 818, 2025. DOI: https://doi.org/10.3390/ph18060818.
FERRI, N. Do anti-PCSK9 monoclonal antibodies have pleiotropic effects? JACC: Basic to Translational Science, v. 10, n. 5, p. 456–462, 2025. DOI: https://doi.org/10.1016/j.jacbts.2025.04.005.
FILINA, Z. V.; LITYUSHKINA, M. I.; ALAYEVA, Z. G. Analysis of methods for normalizing lipid profile and blood pressure in patients with chronic coronary syndromes. Medicine and Biotechnology, v. 15, n. 2, p. 78–84, 2025.
HUMMADI, A. et al. Whole exome sequencing identifies concurrent LDLR and ABCG8 mutations in a Saudi family with familial hypercholesterolemia and sitosterolemia. Frontiers in Genetics, v. 16, p. 1679594, 2025. DOI: https://doi.org/10.3389/fgene.2025.1679594.
KIM, H. L. et al. Real-world effectiveness of rosuvastatin–ezetimibe single pill (Rovazet®) in Korean dyslipidemia patients. Journal of Clinical Medicine, v. 14, n. 15, p. 5480, 2025. DOI: https://doi.org/10.3390/jcm14155480.
LIU, Y. et al. Comparative lipid-lowering effects of statin monotherapy versus statin plus ezetimibe: a meta-analysis. Journal of Clinical Lipidology, v. 15, n. 1, p. 45–52, 2023.
MATHIOUDAKIS, K. et al. Prevalence, incidence, and patterns of lipid-lowering treatment in Greece based on real-world nationwide data on 8,535,780 adults. Hellenic Journal of Cardiology, v. 66, n. 3, p. 213–221, 2025. DOI: https://doi.org/10.1016/j.hjc.2025.04.003.
PRIANI, S. E. et al. Formulation strategies for ezetimibe and its combinations: advancing biopharmaceutical and therapeutic potential. Drug Design, Development and Therapy, v. 19, p. 1357–1369, 2025. DOI: https://doi.org/10.2147/DDDT.S550340.
PARK, S. et al. Efficacy and safety of quadruple-drug fixed-dose single-pill combination therapy for hypertension and dyslipidemia: a prospective, multicenter study. Clinical Therapeutics, v. 47, n. 7, p. 1054–1065, 2025.
PERREGAUX, J. F.; GALLO, A. From histiocytosis to sitosterolemia: a case report. Atherosclerosis, v. 371, p. 122–125, 2025.
VARGHESE, A.; HEGELE, R. A. SAT-248 A case series of heterozygous familial hypercholesterolemia with PCSK9 inhibitor failure. Journal of the Endocrine Society, v. 9, suplemento 1, p. bvaf149.803, 2025.
WEI, H. et al. Effectiveness of fixed-dose rosuvastatin and ezetimibe in managing high cardiovascular risk dyslipidemia patients: a real-world observational study. Current Medical Research and Opinion, v. 39, n. 8, p. 1234–1242, 2024.
